Over the past couple days Sunesis Pharmaceuticals (SNSS) has seen phenomenal returns of 38% or $0.57 per share since last week. Analysts are now saying that this stock could be ready for prime time and skyrocket to over $1 per share for it’s BTK Inhibitor.
Sunesis Pharmaceuticals (SNSS) Analysis
Inflow is higher than Outflow, this tells us that the distribution of order flow is more like distributed to inflow that means investors are currently injecting money into the stock vs out of the stock.
Large order sales has increase today from yesterday’s value of 0.01 to 0.03. The volume of SNSS has increased 450000 from previous volumes. Analysts currently price the stock with an average price target of $3.50 with low target of $1.50 and a high target of $6.00.
Short interest has increase it’s highest since previous trading weeks.
BTK Inhibition is the backbone
Imbruvica was the first BTK inhibitor FDA approved and in 2018 sales were over $2 billion with EvaluatePharma predicting 2024 sales to be over $9 billion which is an increase of $7 billion. Here’s a rough summary of their pipeline candidate:
- Vecabrutinib is well tolerated.
- No grade 3 or higher drug related adverse events above 50mg.
- No drug related bleeding, arthralgia, or cardiac AEs have been reported.
- Evidence of clinical activity was observed in covalent BTKi-relapsed patients with Wild-type BTK and C481-mutated BTK disease.
- Study is currently treating patients at 400mg BID.
Sunesis Pharmaceuticals (SNSS) Phase 3 Results
Analysts have determined that the Phase 3 Results for Sunesis’ trial is currently underway and may be release during the first quarter or second of 2020. Analysts believe that this release may be the catalyst to Sunesis’ launch to $1 or more per share.
According to a slide from the investor presentation, their pipeline candidate is well tolerated, which may be a sign that Phase 3 results will be outstanding. There is a large market these drugs. Buy.
